{"analyses":[{"ciLowerLimit":"-0.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-0.02","estimateComment":"A smaller proportion represents larger benefit.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.019","paramType":"Proportion Difference - Stratified CMH","paramValue":"-0.10","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"87"}],"title":"Dependent"},{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"130"}],"title":"Nondependent"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"description":"RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as having had at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in 8 weeks prior to Week 24 (excluding cases associated with clinically overt bleeding). Participants with the last double-blind phase participation date prior to Day 162 (ie. missing at Week 24) were considered transfusion dependent at Week 24.","groups":[{"description":"Participants received momelotinib plus placebo to match ruxolitinib.\n\nMomelotinib tablets were administered orally once daily at a starting dose of 200 mg.\n\nAdditional available strengths included 100 mg and 150 mg. Placebo to match ruxolitinib tablets were administered orally twice daily.","id":"OG000","title":"Momelotinib (MMB)"},{"description":"Participants received ruxolitinib plus placebo to match momelotinib.\n\nRuxolitinib tablets were administered orally twice daily. The dose ranged from 5 to 20 mg BID and was dependent on platelet count, creatinine clearance, and transaminase levels.\n\nPlacebo to match momelotinib tablets were administered orally once daily.","id":"OG001","title":"Ruxolitinib (RUX)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Week 24","title":"RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)).","type":"SECONDARY","unitOfMeasure":"Participants"}